VIBOSTOLIMAB PLUS PEMBROLIZUMAB WITH/WITHOUT DOCETAXEL VS DOCETAXEL IN NSCLC AFTER PLATINUM CHEMOTHERAPY AND IMMUNOTHERAPY

被引：0
|
作者：
Peters, Solange [1 ]
Lee, Dae Ho [2 ]
Ramlau, Rodryg [3 ]
Halmos, Balazs [4 ]
Schumann, Christian [5 ]
Planchard, David [6 ]
Bhagwati, Niyati [7 ]
Chen, Diana [7 ]
Kush, Debra [7 ]
Novello, Silvia [8 ]
机构：
[1] Univ Lausanne, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
[2] Asan Med Ctr, Seoul, South Korea
[3] Poznan Univ Med Sci, Poznan, Poland
[4] Montefiore Einstein Ctr Canc Care, Dept Oncol, New York, NY USA
[5] Klin Pneumol Thoraxonkol Schlaf & Beatmungsmed, Klinikverbund Allgau, Kempten, Germany
[6] Dept Med Oncol, Thorac Grp, Gustave Roussy, Villejuif, France
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Gonzaga Univ Turin, Azienda Osped Univ San Luigi, Dept Oncol, Orbassano, Italy
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.463
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
463
引用
收藏
页码：A492 / A492
页数：1
相关论文
共 50 条
  • [31] Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel
    Tsuji, Kunihiro
    Kito, Yosuke
    Miyajima, Saori
    Yonezawa, Miwa
    Kubo, Anna
    Ushijima, Kahori
    Doyama, Hisashi
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (01) : 84 - 87
  • [32] DOCETAXEL: RECHALLENGE AT PSA RELAPSE AFTER DOCETAXEL CHEMOTHERAPY AT HORMONE REFRACTORY PROSTATE CANCER
    Firek, P.
    Pfister, D.
    Thueer, D.
    Brehmer, B.
    Epplen, R.
    Heidenreich, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 283 - 283
  • [33] Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel
    Kunihiro Tsuji
    Yosuke Kito
    Saori Miyajima
    Miwa Yonezawa
    Anna Kubo
    Kahori Ushijima
    Hisashi Doyama
    Clinical Journal of Gastroenterology, 2021, 14 : 84 - 87
  • [34] Chemotherapy-induced colitis after docetaxel
    Trigg, NA
    Patel, M
    Hoeltgen, T
    Berkelhammer, C
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S155 - S155
  • [35] Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study
    Matsuzawa, R.
    Morise, M.
    Ito, K.
    Hataji, O.
    Takahashi, K.
    Kuwatsuka, Y.
    Goto, Y.
    Imaizumi, K.
    Itani, H.
    Yamaguchi, T.
    Zenke, Y.
    Oki, M.
    Ishii, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S68 - S68
  • [36] Acute hemorhagic colitis after docetaxel chemotherapy
    Poupeney, S
    Bellaïche, G
    Lapoile, E
    Slama, JL
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2003, 27 (10): : 952 - 954
  • [37] Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1-Strong-Positive NSCLC
    Brahmer, Julie R.
    Gottfried, Maya
    Li, Xiaoyun
    Smith, Margaret
    Rangwala, Reshma A.
    O'Brien, Mary E.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [38] Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
    Lu, S.
    Chen, Z.
    Hu, C.
    Xin-Ling, R.
    Chen, Y.
    Song, Y.
    Qiong, Z.
    Fan, Y.
    Gang, W.
    Zhi-Yong, M.
    Fang, J.
    Qi-Tao, Y.
    Liu, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1807 - S1808
  • [39] Effects of EGFR Mutations on NSCLC Patients Treated by Ramucirumab plus Docetaxel
    Gong, Huanxiu
    Hou, Peifeng
    INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2022, 22 (04) : 256 - 264
  • [40] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC
    Huang, M.
    Pellissier, J.
    Liao, J.
    VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
12345